TOP TEN perturbations for 39891_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39891_at
Selected probe(set): 39891_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39891_at (39891_at) across 6674 perturbations tested by GENEVESTIGATOR:
dendritic cell study 6 (gardiquimod; RN486) / dendritic cell study 6 (untreated)
Relative Expression (log2-ratio):2.4670067Number of Samples:4 / 8
Experimental | dendritic cell study 6 (gardiquimod; RN486) |
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. | |
Control | dendritic cell study 6 (untreated) |
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. |
dendritic cell study 6 (gardiquimod) / dendritic cell study 6 (untreated)
Relative Expression (log2-ratio):2.4264927Number of Samples:7 / 8
Experimental | dendritic cell study 6 (gardiquimod) |
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. | |
Control | dendritic cell study 6 (untreated) |
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. |
glioma study 17 (anaplastic astrocytoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)
Relative Expression (log2-ratio):2.096075Number of Samples:2 / 3
Experimental | glioma study 17 (anaplastic astrocytoma; A2B5+) |
Oligodendrocyte progenitor cells (OPC) isolated from high grade anaplastic astrocytoma (grade III). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 45 ± 18 years old. | |
Control | non-tumor oligodendrocyte progenitor cell sample (cortex) |
Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. |
glioma study 17 (glioblastoma; unsorted) / non-tumor cortical tissue
Relative Expression (log2-ratio):2.029706Number of Samples:2 / 4
Experimental | glioma study 17 (glioblastoma; unsorted) |
Brain cells isolated from high grade glioblastoma (grade IV). Tumor tissue was dissociated using enzymatic treatment and all cells were used for RNA isolation. | |
Control | non-tumor cortical tissue |
Cortical tissue obtained from patients with epilepsy, but without any manifested brain cancer. The tissue was dissociated using enzymatic treatment, but all brain cell types were used for analyses. |
dendritic cell study 6 (gardiquimod; RN486) / dendritic cell study 6 (CpG A; RN486)
Relative Expression (log2-ratio):1.9806252Number of Samples:4 / 4
Experimental | dendritic cell study 6 (gardiquimod; RN486) |
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. | |
Control | dendritic cell study 6 (CpG A; RN486) |
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with CpG-A ODN2216 Class A (TLR9 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+. |
expO lung cancer study 1 (papillary adenocarcinoma, NOS; primary) / expO lung cancer study 1 (neuroendocrine carcinoma; primary)
Relative Expression (log2-ratio):1.9379034Number of Samples:2 / 6
Experimental | expO lung cancer study 1 (papillary adenocarcinoma, NOS; primary) |
Primary tumor tissue samples obtained from the lung of patients with papillary adenocarcinoma (NOS). | |
Control | expO lung cancer study 1 (neuroendocrine carcinoma; primary) |
Primary tumor tissue samples obtained from the lung of patients with neuroendocrine carcinoma. |
expO lung cancer study 1 (squamous cell carcinoma, NOS; primary) / expO lung cancer study 1 (papillary adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):-1.9265528Number of Samples:40 / 2
Experimental | expO lung cancer study 1 (squamous cell carcinoma, NOS; primary) |
Primary tumor tissue samples obtained from the lung of patients with squamous cell carcinoma (NOS). | |
Control | expO lung cancer study 1 (papillary adenocarcinoma, NOS; primary) |
Primary tumor tissue samples obtained from the lung of patients with papillary adenocarcinoma (NOS). |
expO lung cancer study 1 (papillary adenocarcinoma, NOS; primary) / expO lung cancer study 1 (large cell carcinoma, NOS; primary)
Relative Expression (log2-ratio):1.9235601Number of Samples:2 / 9
Experimental | expO lung cancer study 1 (papillary adenocarcinoma, NOS; primary) |
Primary tumor tissue samples obtained from the lung of patients with papillary adenocarcinoma (NOS). | |
Control | expO lung cancer study 1 (large cell carcinoma, NOS; primary) |
Primary tumor tissue samples obtained from the lung of patients with large cell carcinoma (NOS). |
glioma study 17 (astrocytoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)
Relative Expression (log2-ratio):1.7960701Number of Samples:3 / 3
Experimental | glioma study 17 (astrocytoma; A2B5+) |
Oligodendrocyte progenitor cells (OPC) isolated from low grade astrocytoma (grade II). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 36 ± 7 years old. | |
Control | non-tumor oligodendrocyte progenitor cell sample (cortex) |
Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. |
expO lung cancer study 1 (papillary adenocarcinoma, NOS; primary) / expO lung cancer study 1 (bronchiolo-alveolar adenocarcinoma; primary)
Relative Expression (log2-ratio):1.7737255Number of Samples:2 / 13
Experimental | expO lung cancer study 1 (papillary adenocarcinoma, NOS; primary) |
Primary tumor tissue samples obtained from the lung of patients with papillary adenocarcinoma (NOS). | |
Control | expO lung cancer study 1 (bronchiolo-alveolar adenocarcinoma; primary) |
Primary tumor tissue samples obtained from the lung of patients with bronchiolo-alveolar adenocarcinoma. |